Biotechnology company Moderna Inc (Nasdaq:MRNA) and Catalent Inc (NYSE:CTLT), a provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, on Wednesday declared the expansion of a strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of Moderna's COVID-19 vaccine at Catalent's biologics facility in Bloomington, Indiana.
The companies had announced in June 2020 that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Moderna's vaccine. Moderna announced on 29 March 2021 that this milestone was achieved.
Under the newly expanded agreement, Catalent will now dedicate to Moderna's use a new high-speed filling line at the site through to June 2023.
This filling line can be used to manufacture the COVID-19 vaccine and potentially additional investigational programmes in Moderna's clinical pipeline. Catalent will also provide inspection, labelling, cartoning and final packaging for these programmes.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology